Compugen (CGEN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$74.0M

Revenue (quarter)

$2.6M

Revenue growth (year over year)

+107.00%

Gross profit (trailing twelve months)

$64.3M

Gross margin

86.89%

Net income (trailing twelve months)

$35.2M

Net income (quarter)

−$7.0M

Net income growth (year over year)

+4.58%

Net margin

47.55%

Return on equity

50.64%

EPS (trailing twelve months)

$0.38

Book value per share

$0.94

P/E (trailing twelve months)

5.38

Price to book

2.14

Debt to assets

35.87%

Payout ratio

—

Dividend yield

—

Company profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

• Is Compugen (CGEN) profitable?

  Yes. Compugen earned $35.2M in net income over the trailing twelve months, a net margin of 47.55%.

• How much revenue does Compugen (CGEN) make?

  Compugen generated $74.0M in revenue over the trailing twelve months, up 107.00% year over year.

• What is CGEN's P/E ratio?

  Compugen trades at 5.4 times trailing twelve-month earnings, on an EPS of $0.38.

• How do I buy stock in Compugen (CGEN)?

  CGEN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.